Study guide

1.8 Fetal Development

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.8 Fetal Development

Key Takeaways Explain This Topic AI

Organogenesis spans embryonic weeks 3–8 (roughly gestational weeks 5–10 by LMP dating) and is the highest-risk window for major teratogen-related structural anomalies

Nuchal translucency is measured between 11+0 and 13+6 weeks gestational age as part of first-trimester aneuploidy risk assessment

CVS is typically performed at 10–13 weeks; amniocentesis is usually deferred until ≥15 weeks, shaping prenatal counseling timelines

Neural tube closure is normally complete by approximately day 28 post-fertilization; exposures before confirmation of pregnancy can still disrupt this process

Genetic counselors distinguish embryonic age (fertilization) from gestational age (LMP) when interpreting timing of exposures, ultrasound findings, and invasive testing windows

Last updated: August 2026

1.8 Fetal Development

Quick Answer: For genetic counseling, fetal development is a timing map: embryonic weeks 3–8 (organogenesis) are the peak structural teratogen window; NT is measured at 11+0–13+6 weeks; CVS is usually 10–13 weeks and amniocentesis typically ≥15 weeks. Always convert exposure and procedure dates using gestational age (LMP) versus embryonic/post-fertilization age.

Domain 1B expects you to connect embryology to counseling decisions—not to memorize every molecular cascade. Exam items often give an exposure date, an ultrasound finding, or a request for invasive testing and ask whether the timing fits a critical period, a screening window, or a safer diagnostic approach.

Gestational Age vs Embryonic Age

Clinicians date pregnancy by gestational age (GA) from the last menstrual period (LMP), which is about 2 weeks ahead of embryonic (post-fertilization) age . A patient who says “I was 6 weeks pregnant when I took isotretinoin” usually means GA 6 weeks ≈ embryonic week 4—still squarely in organogenesis. Misaligning these clocks is a classic counseling and exam trap.

  • Dating system Zero point Relationship
  • Gestational age (clinical) First day of LMP Standard for ultrasound, NT, CVS/amnio windows
  • Embryonic / fetal age Fertilization ~GA minus 2 weeks; used in embryology texts
  • Carnegie stages Morphologic landmarks Useful for comparing animal/human critical periods
  • Major Developmental Periods

Period Approximate timing Counseling relevance

Pre-embryonic / blastocyst Fertilization → ~week 2 embryonic “All-or-none” concept for many early insults; implantation failure or miscarriage more than discrete organ defect

Embryonic (organogenesis) Embryonic weeks 3–8 (~GA 5–10) Highest risk for major structural malformations from teratogens

Fetal From ~embryonic week 9 to birth Growth, maturation, functional disruption; some teratogens still matter (e.g., brain, teeth, behavior)

Organogenesis is when the three germ layers form organ primordia. After this window, many teratogens cause growth restriction, CNS functional effects, or pregnancy loss rather than classic major malformations—though exceptions exist (e.g., ACE inhibitors in the second/third trimester affecting fetal renal function and skull ossification).

Organ-Specific Critical Periods

Critical periods are when a developing structure is most susceptible. Genetic counselors use them when a patient reports an exposure and asks, “Could this have caused my baby’s heart defect / neural tube defect / cleft?”

Structure / system Peak vulnerability (embryonic timing) Clinical anchors

Neural tube Closure complete by ~ day 28 post-fertilization (~GA 6 weeks) Many patients do not yet know they are pregnant; folate timing counseling is preventive, not only retrospective

Heart ~weeks 3–6 embryonic (looping/septation through organogenesis) Congenital heart disease timing questions; first-trimester teratogen history

  • Limbs ~weeks 4–6 embryonic Thalidomide historical lesson; other limb teratogens
  • Palate / lip Lip ~weeks 5–6; palate ~weeks 6–9 embryonic Orofacial cleft exposure timing

External genitalia / sexual differentiation Later embryonic into early fetal Disorders of sex development differential is broader than timing alone

CNS (ongoing) Continues through fetal life Alcohol, some AEDs, infections—functional and structural effects beyond week 8

Neural Tube and Early Counseling

Because neural tube closure finishes near the end of the first month after fertilization, a “I didn’t know I was pregnant until 7 weeks” history does not rule out an early exposure effect on the neural tube. When counseling prospectively, emphasize preconception folic acid and medication review before organogenesis starts—not only after a positive pregnancy test.

  • Ultrasound Windows Genetic Counselors Must Know
  • Nuchal Translucency (NT)

Nuchal translucency is the sonographic fluid collection behind the fetal neck measured in the first trimester as part of aneuploidy (and some other) risk assessment.

  • Parameter Typical value
  • GA window 11+0 to 13+6 weeks (CRL commonly ~45–84 mm)

Role Component of combined first-trimester screening; increased NT raises concern for aneuploidy, cardiac defects, Noonan spectrum, and other genetic conditions

Counseling link An isolated increased NT still warrants structured follow-up (detailed anatomy, possible microarray/gene testing pathways)—not dismissal as “just a soft marker” without context

Outside 11+0–13+6, NT measurement for standard screening algorithms is not valid in the usual sense; later nuchal fold assessment is a different second-trimester marker.

Anatomy Survey and Growth

The detailed anatomic survey is commonly performed around 18–22 weeks GA . Earlier detection of some anomalies is increasing with first-trimester anatomy skills, but counselors should still set expectations: many structural findings are second-trimester diagnoses. Fetal growth restriction and some functional problems declare later still.

Invasive Prenatal Diagnosis Timing (CVS vs Amniocentesis)

Procedure timing is both a safety and a sample-type issue—and it drives when families can receive diagnostic information.

Procedure Typical GA window Sample Counseling notes

Chorionic villus sampling (CVS) ~ 10–13 weeks Placental villi Earlier diagnostic answer; confined placental mosaicism (CPM) can complicate interpretation; generally avoided very early (<10 weeks) historically due to limb reduction concerns with very early transcervical approaches

Amniocentesis Usually ≥15 weeks (often 15–18+ for genetic indication) Amniotic fluid (fetal cells / DNA) Later than CVS; mosaicism usually reflects true fetal lineage better than placenta; culture failure and timing trade-offs

Exam-style application: a patient at 11 weeks wanting a diagnostic test after a high-risk NIPT is generally in a CVS window (with counseling about CPM and lab method). A patient at 16 weeks after an anatomy finding is typically offered amniocentesis . Neither procedure replaces informed consent about miscarriage risk, which varies by center, operator, and contemporaneous data—quote your institution’s figures, not a memorized universal number.

Twinning Timing (Brief Clinical Link)

Chorionicity and amnionicity reflect when the zygote splits:

  • Split timing (approx.) Result
  • Early (≤ day 3) Dichorionic diamniotic
  • Later (~days 4–8) Monochorionic diamniotic
  • Still later (~days 8–13) Monochorionic monoamniotic
  • Very late Conjoined

Chorionicity matters for twin-twin transfusion risk and for interpreting genetic results (e.g., whether twins share a placenta and how zygosity was assumed).

Putting Timing Together in a Counseling Script

When a consult involves exposure + testing choices, walk the timeline in order:

Convert the exposure to embryonic and gestational age.

Map it onto organ critical periods and the embryonic vs fetal period.

State what ultrasound can and cannot show at the current GA (NT window vs anatomy survey).

Offer diagnostic options that fit the calendar ( CVS vs amnio ), including mosaicism and turnaround implications.

Separate association from proof —an exposure in a critical period raises biological plausibility; it does not automatically prove causation for a specific anomaly.

This developmental clock is the backbone of Domain 1B fetal-development items and reappears in Domain 3 reproductive genetics when choosing prenatal tests.